

# Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer

December 7 2022

---



Credit: Unsplash/CC0 Public Domain

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the

neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

"This is the first report of neoadjuvant T-DXd for [patients](#) with hormone receptor-positive, HER2-low, localized [breast cancer](#)," said Aditya Bardia, MD, MPH, an attending physician at Mass General Cancer Center and director of breast [cancer](#) research and an associate professor at Harvard Medical School. "It could provide the groundwork for future studies with [antibody-drug conjugates](#), including T-DXd, for patients with early-stage breast cancer."

Patients with localized, high-risk breast cancer are often given chemotherapy before undergoing surgery. However, when such tumors express the estrogen receptor and/or the progesterone receptor, the pathological complete response rate to [neoadjuvant chemotherapy](#) is less than 5 percent, necessitating new treatment options, Bardia said.

T-DXd is an antibody-drug conjugate that is internalized into cancer cells upon binding to HER2. Once inside, it releases a cytotoxic payload that causes DNA damage and kills the cancer cell. It is currently approved by the U.S. Food and Drug Administration (FDA) to treat several types of tumors that overexpress HER2, and it was recently approved to treat metastatic breast cancer with low HER2 expression.

"While T-DXd demonstrated impressive efficacy in metastatic HER2-low breast cancer, to date, no trial has evaluated T-DXd in localized, early-stage, potentially curable HER2-low breast cancer, which led us to design this neoadjuvant clinical trial," said Sara Hurvitz, MD, medical director of the Clinical Research Unit at Jonsson Comprehensive Cancer Center, a professor of medicine in the Division

of Hematology/Oncology at the University of California, Los Angeles, and co-author of the study.

Bardia, Hurvitz, and colleagues conducted the phase II TRIO-US B-12 TALENT clinical trial to assess the safety and efficacy of T-DXd when used as a neoadjuvant treatment, either alone or in combination with the aromatase inhibitor anastrozole. At the time of first data cutoff (10/05/2022), 17 patients had completed the planned eight cycles of T-DXd, and 16 patients had completed the planned six cycles of T-DXd plus anastrozole.

According to Bardia, the primary endpoint for the study was a 5 percent pathologic complete response (pCR) rate, defined as complete tumor regression and no lymph node involvement at the time of surgery. At the time of first data cutoff, no patients had experienced a pCR in the combination treatment arm, and one out of 19 patients (5.3 percent) had experienced a pCR in the solo treatment arm.

As of the data cutoff, 33 patients had completed neoadjuvant treatment and undergone surgery, seven patients were awaiting surgery, and 13 patients were still undergoing T-DXd treatment. Among the response-evaluable population, in the solo treatment arm, the overall response rate was 75 percent, including 11 partial responses and one complete response. In the combination treatment arm, the overall response rate was 63 percent, including 10 partial responses and two complete responses.

The most common treatment-related adverse events of grade 3 or higher were hypokalemia, diarrhea, neutropenia, fatigue, headache, vomiting, dehydration, and nausea, each of which occurred in fewer than 6 percent of patients. One patient developed grade 2 interstitial lung disease, which resolved after treatment discontinuation.

Total patient numbers and efficacy data are immature and will be updated at the time of the meeting.

Hurvitz stressed that the clinical outcome results, including pCR and overall response rate, are not mature, as not all patients had scans or underwent surgery by the time of data cutoff. Overall, the tolerability and overall response data were encouraging and may warrant future studies on T-DXd in this patient population, Hurvitz said.

"The study demonstrated that T-DXd was relatively safe in HER2-low, hormone receptor-positive, localized breast cancer. It provides translational framework for future studies, including combination regimens in the neoadjuvant setting to further improve clinical outcomes," Bardia said.

Bardia, Hurvitz and colleagues aim to follow up on this work by analyzing potential biomarkers from tumor tissue and blood samples taken before, during, and after treatment. Bardia hopes these biomarkers will help researchers more accurately assess HER2 status, predict which tumors will have the best responses to T-DXd treatment, and illuminate potential mechanisms of T-DXd resistance.

Limitations of this study include a small sample size characteristic of phase II studies, which did not allow for a formal comparison of the two treatment arms. Additionally, the primary and secondary endpoints of this study assessed response but did not evaluate long-term survival.

**More information:** Conference: [www.sabcs.org/2022-SABCS](http://www.sabcs.org/2022-SABCS)

Trial info: [clinicaltrials.gov/ct2/show/NCT04553770](https://clinicaltrials.gov/ct2/show/NCT04553770)

Provided by American Association for Cancer Research

Citation: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer (2022, December 7) retrieved 4 May 2024 from <https://medicalxpress.com/news/2022-12-neoadjuvant-trastuzumab-deruxtecan-clinical-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.